CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level (Q44346465)

2 December 2017

title

CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level (English)

1 reference

2 December 2017

1 reference

Xu XJ

1

1 reference

2 December 2017

Elfvin A

2

1 reference

2 December 2017

Hao JX

3

1 reference

2 December 2017

Fournié-Zaluski MC

4

1 reference

2 December 2017

Roques BP

5

1 reference

2 December 2017

Wiesenfeld-Hallin Z

6

1 reference

2 December 2017

publication date

1 June 1997

1 reference

2 December 2017

1 reference

2 December 2017

volume

31

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

287-291

1 reference

The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

In vitro and in vivo effects of kelatorphan on enkephalin metabolism in rodent brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

"Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Unlike morphine the endogenous enkephalins protected by RB101 are unable to establish a conditioned place preference in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

The role of CCK caerulein, and CCK antagonists in nociception

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Antisense oligodeoxynucleotide to the CCKB receptor produces naltrindole- and [Leu5]enkephalin antiserum-sensitive enhancement of morphine antinociception

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Cholecystokinin B receptor antagonism enhances the ability of a low dose of morphine to reduce c-Fos expression in the spinal cord of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

The CCK-B antagonist CI988 enhances the reflex-depressive effect of morphine in axotomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Two brain cholecystokinin receptors: implications for behavioral actions.

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260.

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Modification by cholecystokinin octapeptide of the binding of mu-, delta-, and kappa-opioid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Mobilization of calcium from intracellular stores as one of the mechanisms underlying the antiopioid effect of cholecystokinin octapeptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Stimulation of delta-opioid receptors reduces the in vivo binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by κ receptor stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB receptor antagonist L-365,260 in rat spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects

1 reference

https://api.crossref.org/works/10.1016%2FS0143-4179%2897%2990061-5

7 January 2021

10.1016/S0143-4179(97)90061-5

Identifiers

DOI

1 reference

2 December 2017

1 reference